RELEVANCE: Phenotyping is a tool that has been recently introduced in the study of addiction and can be used to improve diagnosis and overall treatment outcomes. It aids in the identification of biological and behavioral markers of severity that can be useful in determining response to treatment. A recent study examined the feasibility and administration of the NIDA Phenotyping Assessment Battery (PhAB), a modular package of assessments and neurocognitive tasks, but the need for a large-scale phenotyping study to further explore the validity and utility of PhAB in clinical trials remains.

DESCRIPTION: This is a multisite observational study that involves administration of an assessment battery (including NIDA PhAB and SUDSS) to individuals meeting DSM-5 criteria for moderate or severe SUD seeking treatment or recently enrolled (within past 90 days) at up to five clinical sites. It aims to evaluate the feasibility, construct validity, and test-retest reliability of the NIDA PhAB and refine it into a very brief battery that can be efficiently embedded in future clinical trials, allowing for aggregation and comparison of data across studies, enhancing scientific yield and advancing personalized medicine for SUD.

STATUS: In development